PerkinElmer, Inc. (PKI)
(Delayed Data from NYSE)
$96.59 USD
+1.71 (1.80%)
Updated May 3, 2019 04:03 PM ET
After-Market: $96.59 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.59 USD
+1.71 (1.80%)
Updated May 3, 2019 04:03 PM ET
After-Market: $96.59 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
5 Reasons Why You Should Buy CONMED (CNMD) Stock Right Now
by Zacks Equity Research
Strong market trends and share price performance fortify CONMED's (CNMD) foothold in the niche markets.
GNC Holdings to Boost International Business With New Deals
by Zacks Equity Research
GNC Holdings (GNC) adopts initiatives to boost contributions from international business with strong focus on China.
GNC Holdings (GNC) Tops Q4 Earnings, Lags Revenue Estimates
by Zacks Equity Research
Despite sluggish performance by manufacturing/wholesale segments, GNC Holdings (GNC) witnesses revenue growth in Q4.
DaVita (DVA) Beats Q4 Earnings Estimates, Misses Revenues
by Zacks Equity Research
Impressive results from Kidney Care business drove DaVita (DVA) in Q4.
Myriad Genetics' Positive Study Data May Expand Customer Base
by Zacks Equity Research
Myriad Genetics (MYGN) leaves no stone unturned to drive the uptake of myRisk Hereditary Cancer test and strengthen the Molecular Diagnostics portfolio.
5 Reasons to Invest in PerkinElmer (PKI) Stock Right Now
by Zacks Equity Research
PerkinElmer (PKI) rides on synergies from the acquisition of EUROIMMUN and broadened product base.
Luminex (LMNX) Beats on Q4 Earnings & Revenues, Issues View
by Zacks Equity Research
Luminex's (LMNX) favorable tidings at the regulatory front in Q4 buoy optimism.
Here's Why You Should Sweep Up Quest Diagnostics Right Now
by Zacks Equity Research
Quest Diagnostics' (DGX) latest acquisitions boost investors' confidence.
Becton, Dickinson Gains on Strong Q1 Results & Acquisitions
by Zacks Equity Research
Acquisition of C.R.Bard and a solid FY18 guidance are key catalysts for Becton, Dickinson (BDX).
Amedisys (AMED) Strong on Home Health, Margin Decline a Woe
by Zacks Equity Research
Amedisys' (AMED) acquisition of Tenet Healthcare's home health and hospice operations in Arizona might help the company deliver high-quality post-acute services in the key markets.
Haemonetics (HAE) Banks on Plasma Franchise, Competition Rife
by Zacks Equity Research
Haemonetics' (HAE) strong end-market demand for plasma-derived biopharmaceuticals continues to drive growth.
Abbott's FreeStyle LibreLink App Now Available in Europe
by Zacks Equity Research
Abbott (ABT) leaves no stone unturned to cash in on the growing popularity of FreeStyle Libre system that eliminates the need for daily finger sticks.
QIAGEN's QFT-Plus Approval in Japan to Expand Customer Base
by Zacks Equity Research
QIAGEN (QGEN) continues to strengthen Molecular Diagnostics business with focus on expanding QuantiFERON-TB Gold Plus customer base.
QIAGEN Strong on Molecular Diagnostics, Competition Rife
by Zacks Equity Research
QIAGEN's (QGEN) top line continues to gain from strength in the Molecular Diagnostics space amid stiff competition and declining HPV sales.
Bruker (BRKR) Beats on Q4 Earnings & Revenues, Issues View
by Zacks Equity Research
Bruker (BRKR) registers organic revenue growth on strength in NANO and BEST platforms in Q4.
Hologic (HOLX) Q1 Earnings & Revenues Top, Margins Down
by Zacks Equity Research
Solid growth at Hologic's (HOLX) Molecular Diagnostics, Breast Health and international business drives the top line in Q1.
Surmodics (SRDX) Beats on Earnings in Q1, Guidance Solid
by Zacks Equity Research
Solid performance in the In Vitro Diagnostics segment drives Surmodics (SRDX) in first-quarter fiscal 2018.
CVS Health (CVS) Q4 Earnings Beat Estimates, '18 View Upbeat
by Zacks Equity Research
A strong Pharmacy Services segment, benefiting from the upside in the specialty services Drives CVS Health's (CVS) topline in Q4.
Cardinal Health (CAH) Beats on Q2 Earnings, Raises '18 View
by Zacks Equity Research
Solid performance at the Medical Segment drove Cardinal Health (CAH) in Q2.
Illumina Banks on Strategic Partnerships, Competition Rife
by Zacks Equity Research
Illumina's (ILMN) recently-signed partnership to distribute Thermo Fisher's Ion AmpliSeq technology is encouraging.
Cardiovascular Systems (CSII) Q2 Earnings Top, Revenues Lag
by Zacks Equity Research
Cardiovascular Systems (CSII) witnesses year-over-year increase in Q2 revenues on strength in both the segments.
STERIS (STE) Q3 Earnings Beat & Revenues Miss, Margins Up
by Zacks Equity Research
STERIS (STE) witnesses year-over-year rise in Q3 revenues on favorable underlying market trends along with new product and service offerings.
Cerner (CERN) Misses Q4 Earnings Estimates, Bookings Soar
by Zacks Equity Research
Despite a decline in earnings year over year, all-time high bookings drive Cerner's (CERN) top line in Q4.
Haemonetics' (HAE) Q3 Earnings Top Estimates, EPS View Up
by Zacks Equity Research
Continued momentum in new business generation and geographical expansions drive Haemonetics (HAE) in the third quarter.
Myriad Genetics (MYGN) Beats on Earnings & Revenues in Q2
by Zacks Equity Research
Myriad Genetics' (MYGN) year over year decline in revenue was in Q2 is disappointing. However, strong demand for GeneSight tests was encouraging.